The group receiving SRP+MTZ+AMX presented greater mean probing depth ( PD ) reduction and clinical attachment gain , a lower number of sites with PD 5mm ( primary outcome variable ) and a reduced number of subjects with 9 of these residual pockets than the control group at 1-year post-therapy ( p < 0.05 ) .